Regeneron Pharmaceuticals, Inc. (REGN) key performance indicators and operating metrics (8 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Non-GAAP net income per diluted share | 9.47 USD_per_share | FY2026-Q1 |
| Sanofi collaboration revenue | 1.61B | FY2026-Q1 |
| Net product sales - EYLEA HD (U.S.) | 468M | FY2026-Q1 |
| EYLEA - U.S. net product sales | 473M | FY2026-Q1 |
| Libtayo global net product sales | 438M | FY2026-Q1 |
| Dupixent U.S. net product sales | 3.56B | FY2026-Q1 |
| Dupixent Patients on Therapy Globally | 1.4M | FY2026-Q1 |
| Total net product sales | 1.59B | FY2025-Q3 |
Back to REGN overview · REGN earnings · REGN holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.